Therapy of migreni's drugs
ARTICLE PDF (Українська)

Keywords

migraine, headache, diagnostic criteria, treatment

How to Cite

Chuprina, G., Parnikoza, T., & Bondarenko, A. (2017). Therapy of migreni’s drugs. East European Journal of Neurology, (5(17), 20-26. https://doi.org/10.33444/2411-5797.2017.5(17).20-26

Abstract

Migraine is one of the most common and debilitating neurological disorders. The article presents modern information on the prevention and treatment of migraine according to the criteria of the International Society of Headache (EFNS). This article presents clinical features and modern recommendations for the purpose of the use of agents that affect the migraine state, taking into account risk factors.  Also considered are individual syndromes, which accompanied by complications of migraine crises, and the ways of their correction.

https://doi.org/10.33444/2411-5797.2017.5(17).20-26
ARTICLE PDF (Українська)

References

1. Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3nd edn. Cephalalgia 2018. №38 (5). Vol. 1-46.
2. Brainin M, Barnes M, Baron JC, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004. Eur J Neurol 2004;11:577-81.
3. Puledda F., Shields K. Non-Pharmacological Approaches for Migraine. Neurotherapeutics. 2018 Apr; 15(2). Vol. 336–345.
4. Evers S, Kropp P, Pothmann R, Heinen F, Ebinger F. Therapie idiopathischer Kopfschmerzen im Kindes- und Jugendalter. Nervenheilkunde 2008;27:1127-37.
5. Gelfand AA, Fullerton HJ, Goadsby PJ. Child neurology: migraine with aura in children. Neurology 2010; 75(5): e16-e19.
6. Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S, American Academy of Neurology Quality Standards Subcommittee. Practice Committee of the Child Neurology Society. Practice parameter: pharmacological treatment of migraine headache in children and adoles cents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 2004; 63:2215-24.
7. Arruda MA, Guidetti V, Galli F, Albuquerque RC, Bigal ME. Primary headaches in childhood – a population-based study. Cephalalgia 2010; 30: 1056-1064.
8. Dodick DW. Migraine. Lancet. 2018. № 391(10127). Vol. 1315-1330.
9. Vollesen A. L, Benemei S., Cortese F., Labastida-Ramírez A., Marchese F., Pellesi L., Romoli M., Ashina M., Lampl C. Migraine and cluster headache - the common link. J Headache Pain. 2018 Sep 21;19(1):89.
10. Lipton R, Scher A, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States:epidemiology and patterns of health care use. Neurology 2002;58:885-94.
11. Scher A, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache 1998;38:497-506.
12. Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache:a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193-210.
13. Tassorelli C., Diener H. C., Dodick D. W., Silberstein S. D., Lipton R. B., Ashina M., Becker W. J., Ferrari M. D., Goadsby P. J., Pozo-Rosich P., Wang S. J. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018;38(5):815-832.
14. Tfelt-Hansen P, Block G, Dahlöf C, et al. Guidelines for controlled trials of drugs in migraine:second edition. Cephalalgia 2000;20:765-86.
15. Pilgrim AJ. The methods used in clinical trials of sumatriptan in migraine. Headache 1993;33:280-93.
16. Chabriat H, Joire JE, Danchot J, Grippon P, Bousser MG. Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo- controlled study. Cephalalgia 1994;14:297- 300.
17. Nebe J, Heier M, Diener HC. Low-dose ibuprofen in selfmedication of mild to moderate headache:a comparison with acetylsalicylic acid and placebo. Cephalalgia 1995;15:531-5.
18. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995;346:923-6.
19. Diener HC, Bussone G, de Liano H, et al., EMSASI Study Group. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004;24:947-54.
20. Havanka-Kanniainen H. Treatment of acute migraine attack:ibuprofen and placebo compared. Headache 1989;29:507-9.
21. Kloster R, Nestvold K, Vilming ST. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia 1992;12:169-71.
22. Karachalios GN, Fotiadou A, Chrisikos N, Karabetsos A, Kehagioglou K. Treatment of acute  migraine attack with diclofenac sodium:a doubleblind study. Headache 1992;32:98-100.
23. Dahlof C, Bjorkman R. Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia 1993;13:117-23.
24. The Diclofenac-K/Sumatriptan Migraine Study Group.Acute treatment of migraine attacks:efficacy and safety of a nonsteroidal antiinflammatory drug, diclofenac potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 1999;19:232-40.
25. Gobel H, Heinze A, Niederberger U, Witt T, Zumbroich V. Efficacy of phenazone in the treatment of acute migraine attacks:a double-blind, placebo-controlled, randomized study. Cephalalgia 2004;24:888-93.
26. Tulunay FC, Ergun H, Gulmez SE, et al. The efficacy and safety of dipyrone (Novalgin) tablets in the treatment of acute migraine attacks:a double-blind, cross-over, randomized, placebo-controlled, multi- center study. Funct Neurol 2004;19:197-202.
27. Myllyla VV, Havanka H, Herrala L, et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine:comparable effect in a double-blind, randomized, controlled, parallel- group study. Headache 1998;38:201-7.
28. Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M. Efficacy and safety of acetaminophen in the treatment of migraine:results of a randomized, double-blind, placebo-controlled, population- based study. Arch Intern Med 2000;160:3486-92.
29. Lipton RB, Stewart WF, Ryan RE, Saper J, Silberstein S, Sheftell F. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain - three double-blind, randomized, placebo-controlled trials. Arch Neurol 1998;55:210-7.
30. Diener H, Pfaffenrath V, Pageler L. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multi-centre, randomized, double- blind, single- dose, placebo-controlled parallel group study. Cephalalgia 2005;25:776-87.
31. Goldstein J, Silberstein SD, Saper JR, Ryan RE Jr, Lipton RB. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine:results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo- controlled study. Headache 2006;46:444-53.
32. Limmroth V, May A, Diener HC. Lysine- acetylsalicylic acid in acute migraine attacks. Eur Neurol 1999;41:88-93.
33. Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: a randomized, double blind, placebo controlled study. Headache 2002;42:862-71.
34. Diener HC, Eikermann A, Gessner U, et al. Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. Eur Neurol 2004;52:50-6.
35. Lampl C, Voelker M, Diener HC. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol 2007;254:705-12.
36. Kudrow D, Thomas HM, Ruoff G, et al. Valdecoxib for treatment of a single, acute, moderate to severe migraine headache. Headache 2005;45:1151-62.
37. Misra UK, Jose M, Kalita J. Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial. Postgrad Med J 2004;80:720-3.
38. Saper J, Dahlof C, So Y, Tfelt-Hansen P, et al. Rofecoxib in the acute treatment of migraine: a randomized controlled clinical trial. Headache 2006;46:264-75.
39. Silberstein S, Tepper S, Brandes J, et al. Randomised placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 2004;62:1552-7.
40. Ross-Lee LM, Eadie MJ, Heazlewood V, Bochner F, Tyrer JH. Aspirin pharmacokinetics in migraine. The effect of metoclopramide. Eur J Clin Pharmacol 1983;24:777-85.
41. Waelkens J. Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia 1984;4:85-90.
42. Schulman E, Dermott K. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache 2003;43:729-33.
43. Ellis GL, Delaney J, DeHart DA, Owens A. The efficacy of metoclopramide in the treatment of migraine headache. Ann Emerg Med 1993;22:191-5. 
44. Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology 2005;64:463-8.
45. Tfelt-Hansen P, Saxena PR, Dahlof C, et al. Ergotamine in the acute treatment of migraine. A review and European consensus. Brain 2000;123:9-18.
46. The Multinational Oral Sumatriptan Cafergot Comparative Study Group. A randomized, double- blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol 1991;31:314-22.
47. Diener HC, Reches A, Pascual J, Pascual J, Pitei D, Steiner, TJ, Eletriptan and Cafergot Comparative Study Group. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine:a multicentre, randomised, double-blind, placebo-controlled comparison. Europ Neurol 2002;47:99-107.
48. Lainez MJ, Galvan J, Heras J, Vila C. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. Eur J Neurol 2007;14:269-75.
49. Christie S, Gobel H, Mateos V, Allen C, Vrijens F, Shivaprakash M, Rizatriptan-Ergotamine/Caffeine Preference Study Group. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur Neurol 2003;49:20-9.
50. Evers S, Gralow I, Bauer B, et al. Sumatriptan and ergotamine overuse and drug-induced headache:a clinicoepidmiologic study. Clin Neuropharmacol 1999;22:201-6.
51. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-75
52. Goadsby PB, Lipton RB, Ferrai MD. Migraine: current understanding and management. N Engl J Med 2002;346:257-70.
53. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 1992;32:177-84.
54. Geraud G, Compagnon A, Rossi A. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur Neurol 2002;47:88-98.
55. Diamond M, Hettiarachchi J, Hilliard B, Sands G.Nett R. Effectiveness of eletriptan in acute migraine:primary care for Excedrin nonresponders. Headache 2004;44:209-16.
56. Diener HC, for the ASASUMAMIG Study Group. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double- dummy, randomized, multicenter, parallel group study. Cephalalgia 1999;19:581-8.
57. Winner P, Ricalde O, Force BL, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996;53:180-4.
58. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002;42:28-31.
59. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004;55:19-26.
60. Dowson A, Massiou H, Lainez J, Cabarrocas X. Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache 2004;44:318-22.
61. Cady R, Martin V, Mauskop A, et al. Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache 2006;46:914-24.
62. Goadsby PJ, Zanchin G, Geraud G, et al. Early versus non-early intervention in acute migraine -Act when Mild - AwM'. A double-blind placebo- controlled trial of almotriptan. Cephalalgia 2008;28:383-91.
63. Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Almas M, Parsons B. Identification of negative predictors of pain-free response to triptans: analysis of the eletriptan database. Cephalalgia 2008;28:35-40.
64. Linde M, Mellberg A, Dahlof C. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia 2006;26:113-21.
65. Cady R, Martin V, Mauskop A, et al. Symptoms of cutaneous sensitivity pre-treatment and post- treatment: results from the rizatriptan TAME studies. Cephalalgia 2007;27:1055-60.
66. Bigal ME, Serrano D, Buse D, Scher A, Stewart 77. WF.Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine:a longitudinal population-based study. Headache 2008;48:1157-68.
67. Limmroth V, Kazarawa S, Fritsche G, Diener HC. Headache after frequent use of new serotonin agonists zolmitriptan and naratriptan. Lancet 79.
68. Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V. Clinical features of withdrawal 80. headache following overuse of triptans and other headache drugs. Neurology 2001;57:1694-8.
69. Ferrari MD. How to assess and compare drugs in 81. the management of migraine:success rates in terms of response and recurrence. Cephalalgia 1999; 19 (Suppl 23):2-8. 82
70. Ferrari MD, James MH, Bates D, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 83. 1994;14:330-8.
71. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan- 84. naproxen for acute treatment of migraine:a randomized trial. JAMA 2007;297:1443-54.
72. Freitag F, Diamond M, Diamond S, Janssen I, Rodgers A, Skobieranda F. Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache 2008;48:921-30.
73. Bigal M, Sheftell F, Tepper S, Tepper D, Ho TW, 86. Rapoport A. A randomized double-blind study comparing rizatrip tan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine. Headache 2008;48:1286-93. 87.
74. Diener HC, Gendolla A, Gebert I, Beneke M. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, 88. randomized trial. Headache 2005;45:874-82.
75. Stark S, Spierings EL, McNeal S, Putnam GP, Bolden-Watson CP, O'Quinn S. Naratriptan efficacy in migraineurs who respond poorly to oral 89. sumatriptan. Headache 2000;40:513-20.
76. O'Quinn S, Davis RL, Guttermann DL, et al. Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for the acute treatment of migraine. Cephalalgia 1999;19:223-31.
77. Welch KMA, Mathew NT, Stone P, Rosamond W, Saiers J, Gutterman D. Tolerability of sumatriptanxlinical trials and post-marketing experience. Cephalalgia 2000;20:687-95.
78. Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM. Severe vascular events in migraine patients. Headache 2004;44:642-51.
79. Hall G, Brown M, Mo J, MacRae KD. Triptans in migraine:the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004;62:563-8.
80. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994;44:1587-92.
81. Olesen J, Diener HC, Schoenen J, Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. Europ. J Neurol 2004;11:671-7.
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.